Cytarabine Hydrochloride

DRUG2 trials

Sponsors

Sumithira Vasu, Race Oncology Ltd

Conditions

Acute Myeloid LeukemiaAllogeneic Stem Cell Transplant RecipientBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaHigher Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Phase 1

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

CompletedNCT04220684

Sumithira VasuAllogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia +1

Start: 2020-06-11End: 2024-10-22Updated: 2026-01-09

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

WithdrawnNCT05456269

Race Oncology LtdAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Higher Risk Myelodysplastic Syndrome +2

Start: 2022-07-29End: 2023-08-31Updated: 2023-10-03

Related Papers

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2021-11-055 citations

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2020-11-042 citations

A phase I clinical trial testing the safety of IL-21-expanded, off-the-shelf, natural killer cells for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Journal of Clinical Oncology2020-05-206 citations